The US Food and Drug Administration have approved Incyte Corporation’s Jakafi. Jakafi has been the first drug that has been approved for the disease and will now be used to treat patients with polycythemia vera (PV), which is a very rare blood cancer. The patients suffering from PV fail to maintain a consistency in the blood count level in the body, and also hematocrit levels. They have also high risk of blood clotting.
“The team at Incyte is proud that a second indication has been approved for Jakafi, further confirming the strength of our science and our commitment to discovering and developing innovative treatments for patients with cancer,” said Hervé Hoppenot, Incyte’s president and chief executive officer.